Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha radiation consists of alpha particles, which are the nuclei of helium-4 atoms (two protons and two neutrons), highly ionizing and energetic but with very low penetration—they are stopped by a few centimeters of air or by the outer layer of human skin. Internally, alpha emitters are hazardous: if radioactive material emitting alpha particles is inhaled, ingested, or enters a wound, severe, localized DNA and tissue damage can result, raising the risk for cancer and other pathology. These properties also make alpha emitters promising for targeted cancer therapy, where their destructive power is directed specifically to tumor cells (targeted alpha therapy).
Induces dense ionization and double-strand DNA breaks (cytotoxicity) when internalized into tissues. High linear energy transfer (LET) leads to complex/catastrophic DNA lesions, immune activation.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Alpha particle (α (or He²⁺, ⁴₂He²⁺)).